School of Medicine


Showing 1-8 of 8 Results

  • Teresa Wang

    Teresa Wang

    Klaus Bensch Professor in Experimental Pathology, Emerita

    Current Research and Scholarly Interests The main focus of our research is to understand how cells maintain genome integrity by checkpoint mechanisms during chromosome replication.

  • Roger Warnke

    Roger Warnke

    Ronald F. Dorfman, M.B.B.ch., FRCPath, Professor in Hematopathology, Emeritus

    Current Research and Scholarly Interests As an Emeritus Professor, I no longer have a research laboratory and devote my 10% voluntary effort to lymphoma diagnosis and teaching. I do devote a small amount of effort to lymphoma research in collaboration with Yaso Natkunam and others in the Department of Pathology.

  • Irving Weissman

    Irving Weissman

    Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia & D.K. Ludwig Professor for Clinical Investigation in Cancer Research, Professor of Developmental Biology and, by courtesy, of Biology

    Current Research and Scholarly Interests Stem cell and cancer stem cell biology; development of T and B lymphocytes; cell-surface receptors for oncornaviruses in leukemia. Hematopoietic stem cells; Lymphocyte homing, lymphoma invasiveness and metastasis.

  • Gerlinde Wernig

    Gerlinde Wernig

    Assistant Professor of Pathology at the Stanford University Medical Center

    Current Research and Scholarly Interests Fibrotic diseases kill more people than cancer in this country and worldwide. We believe that scar-forming cells called fibroblasts are at the core of the fibrotic response in parenchymal organ fibrosis in the lung, liver, skin, bone marrow and tumor stroma. At the cellular level we think of fibrosis as a step wise process which implicates inflammation and fibrosis. We seek to identify new effective immune therapy targets to treat fibrotic diseases.

  • Marius Wernig

    Marius Wernig

    Professor of Pathology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly Interests Epigenetic Reprogramming, Direct conversion of fibroblasts into neurons, Pluripotent Stem Cells, Neural Differentiation: implications in development and regenerative medicine

  • Robert West

    Robert West

    Professor of Pathology at the Stanford University Medical Center

    Current Research and Scholarly Interests Rob West, MD, PhD, is a Professor of Pathology at Stanford University Medical Center. He is a clinician scientist with experience in translational genomics research to identify new prognostic and therapeutic markers in cancer. His research focus is on the progression of neoplasia to carcinoma. His lab has developed spatially oriented in situ methods to study archival specimens. He also serves as a surgical pathologist specializing in breast pathology.

  • Kitch Wilson

    Kitch Wilson

    Instructor, Pathology

    Current Research and Scholarly Interests I'm interested in both basic and translational cardiovascular biology, regenerative medicine and genomics. Much of my work merges next generation sequencing (NGS) with iPS cell models to find and characterize primate-specific elements within the noncoding genome (lncRNAs, transposable elements, enhancers). Some of these primate elements appear to regulate heart development, disease and even evolution, and with the enormous growth in pluripotent cell technologies their functions can now be experimentally studied. In translational work, I'm developing custom targeted NGS assays for identifying the DNA mutations that underlie cardiomyopathies and other heart diseases.

  • Monte Winslow

    Monte Winslow

    Associate Professor of Genetics and of Pathology

    Current Research and Scholarly Interests Our laboratory uses genome-wide methods to uncover alterations that drive cancer progression and metastasis in genetically-engineered mouse models of human cancers. We combine cell-culture based mechanistic studies with our ability to alter pathways of interest during tumor progression in vivo to better understand each step of metastatic spread and to uncover the therapeutic vulnerabilities of advanced cancer cells.